NCT06953271View on ClinicalTrials.gov

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

164

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 1, 2026

Study Completion Date

January 1, 2027

Conditions
Overactive Bladder (OAB)Urinary Tract Infection (Diagnosis)
Interventions
DRUG

Methenamine Hippurate

Drug: Methenamine hippurate 1 gram by mouth twice daily for three days.

DRUG

Typically prescribed oral antibiotic prophylaxis

Drug: typically prescribed oral antibiotic prophylaxis following intradetrusor BOTOX-A injections. This includes, but is not limited to, antibiotic medications such as nitrofurantoin, amoxicillin/clavulanic acid, and trimethoprim/sulfamethoxazole. Dosage will be determined per usual care. Duration of treatment will be standardized to three days.

Trial Locations (1)

02903

Women & Infants Hospital, Providence

All Listed Sponsors
lead

Women and Infants Hospital of Rhode Island

OTHER